Key points are not available for this paper at this time.
Anti-complement and FcRn treatments both proved to be effective in MG patients, whereas rituximab did not show a significant benefit for patients. Within the limitations of this meta-analysis, including efficacy time points, FcRn treatments showed a greater effect on QMG score in the short term. Real-life studies with long-term measurements are needed to confirm our results.
Saccà et al. (Fri,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: